Loading…
The association between metabolic abnormality and endometrial cancer: A large case-control study in China
Abstract Objectives. To investigate the association between insulin-resistance-related conditions (comprising the metabolic syndrome) and endometrial cancer risk in Chinese women. Methods. We conducted a large case-control study including 942 endometrial cancers and 1721 controls on a Chinese popula...
Saved in:
Published in: | Gynecologic oncology 2010-04, Vol.117 (1), p.41-46 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c479t-f63c3aecd65aeff37456a8462eddb50eb8c3c513289320c15bdcf0cf7eae633e3 |
---|---|
cites | cdi_FETCH-LOGICAL-c479t-f63c3aecd65aeff37456a8462eddb50eb8c3c513289320c15bdcf0cf7eae633e3 |
container_end_page | 46 |
container_issue | 1 |
container_start_page | 41 |
container_title | Gynecologic oncology |
container_volume | 117 |
creator | Zhang, Yan Liu, Zhiwei Yu, Xinchun Zhang, Xiaofei Lü, Shiming Chen, Xiaoduan Lü, Bingjian |
description | Abstract Objectives. To investigate the association between insulin-resistance-related conditions (comprising the metabolic syndrome) and endometrial cancer risk in Chinese women. Methods. We conducted a large case-control study including 942 endometrial cancers and 1721 controls on a Chinese population. The relative endometrial cancer risks from various factors were calculated by the х2 test. Menopausal status and BMI were applied as potential confounders to analyze the joint effects with other factors. Results. We found that overweight/obesity, hypertension, diabetes mellitus and glucose metabolic disturbance were all associated with endometrial cancer risk. Effective medication on diabetes can significantly decrease cancer risk (uncontrolled diabetes: RR = 5.563, 95% CI = 2.406–12.859, p < 0.001; controlled diabetes: RR = 1.331, 95% CI = 0.529–3.352, p > 0.05) as compared with normal controls. Serum lipids were also found to be linked to endometrial cancer risk: positive correlations were present with total serum cholesterol, triglycerides, low-density lipoprotein cholesterol and dyslipidaemia, while a negative correlation was found with high-density lipoprotein cholesterol. We also observed an elevated risk for type I endometrial cancer (OR = 1.839, 95% CI = 1.539–2.197, p < 0.001) in women with BMI ≥ 24.58 versus those with BMI < 24.58, but not for type II cancer (OR = 1.092, 95% CI = 0.969–1.231, p > 0.05). Conclusions. Our findings support the hypothesis that metabolic abnormalities or insulin resistance may promote the initiation and progression of endometrial cancer. The effective treatment of type 2 diabetes might contribute to endometrial cancer prevention. |
doi_str_mv | 10.1016/j.ygyno.2009.12.029 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733802672</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0090825810000041</els_id><sourcerecordid>733802672</sourcerecordid><originalsourceid>FETCH-LOGICAL-c479t-f63c3aecd65aeff37456a8462eddb50eb8c3c513289320c15bdcf0cf7eae633e3</originalsourceid><addsrcrecordid>eNqFkU2LFDEQhoMo7uzqLxAkN0_d5mP6S1BYBl2FBQ-u55CuVO9mTCdrklb635t2Vg9ezCWEep8q8hQhLzirOePt62O93q4-1IKxoeaiZmJ4RHacDU3V9s3wmOxKgVW9aPozcp7SkTEmGRdPydmGtIPgO2Jv7pDqlAJYnW3wdMT8E9HTGbMeg7NA9ehDnLWzeaXaG4rehFKNVjsK2gPGN_SSOh1vsbwTVhB8jsHRlBezUuvp4c56_Yw8mbRL-PzhviBfP7y_OXysrj9ffTpcXlew74ZcTa0EqRFM22icJtntm1b3-1agMWPDcOxBQsOl6AcpGPBmNDAxmDrU2EqJ8oK8OvW9j-H7gimr2SZA57THsCTVSdkz0XaiJOUpCTGkFHFS99HOOq6KM7UpVkf1W7HafCkuVFFcqJcP_ZdxRvOX-eO0BN6eAlh--cNiVAksFk_GRoSsTLD_GfDuHx6c9Ra0-4YrpmNYoi8CFVepAOrLtuVtyZxtZ8_lL2JNpQ8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733802672</pqid></control><display><type>article</type><title>The association between metabolic abnormality and endometrial cancer: A large case-control study in China</title><source>ScienceDirect Freedom Collection</source><creator>Zhang, Yan ; Liu, Zhiwei ; Yu, Xinchun ; Zhang, Xiaofei ; Lü, Shiming ; Chen, Xiaoduan ; Lü, Bingjian</creator><creatorcontrib>Zhang, Yan ; Liu, Zhiwei ; Yu, Xinchun ; Zhang, Xiaofei ; Lü, Shiming ; Chen, Xiaoduan ; Lü, Bingjian</creatorcontrib><description>Abstract Objectives. To investigate the association between insulin-resistance-related conditions (comprising the metabolic syndrome) and endometrial cancer risk in Chinese women. Methods. We conducted a large case-control study including 942 endometrial cancers and 1721 controls on a Chinese population. The relative endometrial cancer risks from various factors were calculated by the х2 test. Menopausal status and BMI were applied as potential confounders to analyze the joint effects with other factors. Results. We found that overweight/obesity, hypertension, diabetes mellitus and glucose metabolic disturbance were all associated with endometrial cancer risk. Effective medication on diabetes can significantly decrease cancer risk (uncontrolled diabetes: RR = 5.563, 95% CI = 2.406–12.859, p < 0.001; controlled diabetes: RR = 1.331, 95% CI = 0.529–3.352, p > 0.05) as compared with normal controls. Serum lipids were also found to be linked to endometrial cancer risk: positive correlations were present with total serum cholesterol, triglycerides, low-density lipoprotein cholesterol and dyslipidaemia, while a negative correlation was found with high-density lipoprotein cholesterol. We also observed an elevated risk for type I endometrial cancer (OR = 1.839, 95% CI = 1.539–2.197, p < 0.001) in women with BMI ≥ 24.58 versus those with BMI < 24.58, but not for type II cancer (OR = 1.092, 95% CI = 0.969–1.231, p > 0.05). Conclusions. Our findings support the hypothesis that metabolic abnormalities or insulin resistance may promote the initiation and progression of endometrial cancer. The effective treatment of type 2 diabetes might contribute to endometrial cancer prevention.</description><identifier>ISSN: 0090-8258</identifier><identifier>EISSN: 1095-6859</identifier><identifier>DOI: 10.1016/j.ygyno.2009.12.029</identifier><identifier>PMID: 20096921</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Body Mass Index ; Case-Control Studies ; China - epidemiology ; Diabetes mellitus ; Diabetes Mellitus - epidemiology ; Diabetes Mellitus - metabolism ; Endometrial cancer ; Endometrial Neoplasms - epidemiology ; Endometrial Neoplasms - metabolism ; Endometrial Neoplasms - pathology ; Female ; Hematology, Oncology and Palliative Medicine ; Humans ; Hypertension - epidemiology ; Hypertension - metabolism ; Menopause ; Metabolic syndrome ; Metabolic Syndrome - epidemiology ; Metabolic Syndrome - metabolism ; Neoplasm Staging ; Obesity ; Obstetrics and Gynecology ; Risk Factors ; Serum lipid</subject><ispartof>Gynecologic oncology, 2010-04, Vol.117 (1), p.41-46</ispartof><rights>Elsevier Inc.</rights><rights>2010 Elsevier Inc.</rights><rights>Copyright 2010 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c479t-f63c3aecd65aeff37456a8462eddb50eb8c3c513289320c15bdcf0cf7eae633e3</citedby><cites>FETCH-LOGICAL-c479t-f63c3aecd65aeff37456a8462eddb50eb8c3c513289320c15bdcf0cf7eae633e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20096921$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Yan</creatorcontrib><creatorcontrib>Liu, Zhiwei</creatorcontrib><creatorcontrib>Yu, Xinchun</creatorcontrib><creatorcontrib>Zhang, Xiaofei</creatorcontrib><creatorcontrib>Lü, Shiming</creatorcontrib><creatorcontrib>Chen, Xiaoduan</creatorcontrib><creatorcontrib>Lü, Bingjian</creatorcontrib><title>The association between metabolic abnormality and endometrial cancer: A large case-control study in China</title><title>Gynecologic oncology</title><addtitle>Gynecol Oncol</addtitle><description>Abstract Objectives. To investigate the association between insulin-resistance-related conditions (comprising the metabolic syndrome) and endometrial cancer risk in Chinese women. Methods. We conducted a large case-control study including 942 endometrial cancers and 1721 controls on a Chinese population. The relative endometrial cancer risks from various factors were calculated by the х2 test. Menopausal status and BMI were applied as potential confounders to analyze the joint effects with other factors. Results. We found that overweight/obesity, hypertension, diabetes mellitus and glucose metabolic disturbance were all associated with endometrial cancer risk. Effective medication on diabetes can significantly decrease cancer risk (uncontrolled diabetes: RR = 5.563, 95% CI = 2.406–12.859, p < 0.001; controlled diabetes: RR = 1.331, 95% CI = 0.529–3.352, p > 0.05) as compared with normal controls. Serum lipids were also found to be linked to endometrial cancer risk: positive correlations were present with total serum cholesterol, triglycerides, low-density lipoprotein cholesterol and dyslipidaemia, while a negative correlation was found with high-density lipoprotein cholesterol. We also observed an elevated risk for type I endometrial cancer (OR = 1.839, 95% CI = 1.539–2.197, p < 0.001) in women with BMI ≥ 24.58 versus those with BMI < 24.58, but not for type II cancer (OR = 1.092, 95% CI = 0.969–1.231, p > 0.05). Conclusions. Our findings support the hypothesis that metabolic abnormalities or insulin resistance may promote the initiation and progression of endometrial cancer. The effective treatment of type 2 diabetes might contribute to endometrial cancer prevention.</description><subject>Body Mass Index</subject><subject>Case-Control Studies</subject><subject>China - epidemiology</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus - epidemiology</subject><subject>Diabetes Mellitus - metabolism</subject><subject>Endometrial cancer</subject><subject>Endometrial Neoplasms - epidemiology</subject><subject>Endometrial Neoplasms - metabolism</subject><subject>Endometrial Neoplasms - pathology</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Hypertension - epidemiology</subject><subject>Hypertension - metabolism</subject><subject>Menopause</subject><subject>Metabolic syndrome</subject><subject>Metabolic Syndrome - epidemiology</subject><subject>Metabolic Syndrome - metabolism</subject><subject>Neoplasm Staging</subject><subject>Obesity</subject><subject>Obstetrics and Gynecology</subject><subject>Risk Factors</subject><subject>Serum lipid</subject><issn>0090-8258</issn><issn>1095-6859</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNqFkU2LFDEQhoMo7uzqLxAkN0_d5mP6S1BYBl2FBQ-u55CuVO9mTCdrklb635t2Vg9ezCWEep8q8hQhLzirOePt62O93q4-1IKxoeaiZmJ4RHacDU3V9s3wmOxKgVW9aPozcp7SkTEmGRdPydmGtIPgO2Jv7pDqlAJYnW3wdMT8E9HTGbMeg7NA9ehDnLWzeaXaG4rehFKNVjsK2gPGN_SSOh1vsbwTVhB8jsHRlBezUuvp4c56_Yw8mbRL-PzhviBfP7y_OXysrj9ffTpcXlew74ZcTa0EqRFM22icJtntm1b3-1agMWPDcOxBQsOl6AcpGPBmNDAxmDrU2EqJ8oK8OvW9j-H7gimr2SZA57THsCTVSdkz0XaiJOUpCTGkFHFS99HOOq6KM7UpVkf1W7HafCkuVFFcqJcP_ZdxRvOX-eO0BN6eAlh--cNiVAksFk_GRoSsTLD_GfDuHx6c9Ra0-4YrpmNYoi8CFVepAOrLtuVtyZxtZ8_lL2JNpQ8</recordid><startdate>20100401</startdate><enddate>20100401</enddate><creator>Zhang, Yan</creator><creator>Liu, Zhiwei</creator><creator>Yu, Xinchun</creator><creator>Zhang, Xiaofei</creator><creator>Lü, Shiming</creator><creator>Chen, Xiaoduan</creator><creator>Lü, Bingjian</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100401</creationdate><title>The association between metabolic abnormality and endometrial cancer: A large case-control study in China</title><author>Zhang, Yan ; Liu, Zhiwei ; Yu, Xinchun ; Zhang, Xiaofei ; Lü, Shiming ; Chen, Xiaoduan ; Lü, Bingjian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c479t-f63c3aecd65aeff37456a8462eddb50eb8c3c513289320c15bdcf0cf7eae633e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Body Mass Index</topic><topic>Case-Control Studies</topic><topic>China - epidemiology</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus - epidemiology</topic><topic>Diabetes Mellitus - metabolism</topic><topic>Endometrial cancer</topic><topic>Endometrial Neoplasms - epidemiology</topic><topic>Endometrial Neoplasms - metabolism</topic><topic>Endometrial Neoplasms - pathology</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Hypertension - epidemiology</topic><topic>Hypertension - metabolism</topic><topic>Menopause</topic><topic>Metabolic syndrome</topic><topic>Metabolic Syndrome - epidemiology</topic><topic>Metabolic Syndrome - metabolism</topic><topic>Neoplasm Staging</topic><topic>Obesity</topic><topic>Obstetrics and Gynecology</topic><topic>Risk Factors</topic><topic>Serum lipid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Yan</creatorcontrib><creatorcontrib>Liu, Zhiwei</creatorcontrib><creatorcontrib>Yu, Xinchun</creatorcontrib><creatorcontrib>Zhang, Xiaofei</creatorcontrib><creatorcontrib>Lü, Shiming</creatorcontrib><creatorcontrib>Chen, Xiaoduan</creatorcontrib><creatorcontrib>Lü, Bingjian</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Yan</au><au>Liu, Zhiwei</au><au>Yu, Xinchun</au><au>Zhang, Xiaofei</au><au>Lü, Shiming</au><au>Chen, Xiaoduan</au><au>Lü, Bingjian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The association between metabolic abnormality and endometrial cancer: A large case-control study in China</atitle><jtitle>Gynecologic oncology</jtitle><addtitle>Gynecol Oncol</addtitle><date>2010-04-01</date><risdate>2010</risdate><volume>117</volume><issue>1</issue><spage>41</spage><epage>46</epage><pages>41-46</pages><issn>0090-8258</issn><eissn>1095-6859</eissn><abstract>Abstract Objectives. To investigate the association between insulin-resistance-related conditions (comprising the metabolic syndrome) and endometrial cancer risk in Chinese women. Methods. We conducted a large case-control study including 942 endometrial cancers and 1721 controls on a Chinese population. The relative endometrial cancer risks from various factors were calculated by the х2 test. Menopausal status and BMI were applied as potential confounders to analyze the joint effects with other factors. Results. We found that overweight/obesity, hypertension, diabetes mellitus and glucose metabolic disturbance were all associated with endometrial cancer risk. Effective medication on diabetes can significantly decrease cancer risk (uncontrolled diabetes: RR = 5.563, 95% CI = 2.406–12.859, p < 0.001; controlled diabetes: RR = 1.331, 95% CI = 0.529–3.352, p > 0.05) as compared with normal controls. Serum lipids were also found to be linked to endometrial cancer risk: positive correlations were present with total serum cholesterol, triglycerides, low-density lipoprotein cholesterol and dyslipidaemia, while a negative correlation was found with high-density lipoprotein cholesterol. We also observed an elevated risk for type I endometrial cancer (OR = 1.839, 95% CI = 1.539–2.197, p < 0.001) in women with BMI ≥ 24.58 versus those with BMI < 24.58, but not for type II cancer (OR = 1.092, 95% CI = 0.969–1.231, p > 0.05). Conclusions. Our findings support the hypothesis that metabolic abnormalities or insulin resistance may promote the initiation and progression of endometrial cancer. The effective treatment of type 2 diabetes might contribute to endometrial cancer prevention.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>20096921</pmid><doi>10.1016/j.ygyno.2009.12.029</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0090-8258 |
ispartof | Gynecologic oncology, 2010-04, Vol.117 (1), p.41-46 |
issn | 0090-8258 1095-6859 |
language | eng |
recordid | cdi_proquest_miscellaneous_733802672 |
source | ScienceDirect Freedom Collection |
subjects | Body Mass Index Case-Control Studies China - epidemiology Diabetes mellitus Diabetes Mellitus - epidemiology Diabetes Mellitus - metabolism Endometrial cancer Endometrial Neoplasms - epidemiology Endometrial Neoplasms - metabolism Endometrial Neoplasms - pathology Female Hematology, Oncology and Palliative Medicine Humans Hypertension - epidemiology Hypertension - metabolism Menopause Metabolic syndrome Metabolic Syndrome - epidemiology Metabolic Syndrome - metabolism Neoplasm Staging Obesity Obstetrics and Gynecology Risk Factors Serum lipid |
title | The association between metabolic abnormality and endometrial cancer: A large case-control study in China |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T20%3A05%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20association%20between%20metabolic%20abnormality%20and%20endometrial%20cancer:%20A%20large%20case-control%20study%20in%20China&rft.jtitle=Gynecologic%20oncology&rft.au=Zhang,%20Yan&rft.date=2010-04-01&rft.volume=117&rft.issue=1&rft.spage=41&rft.epage=46&rft.pages=41-46&rft.issn=0090-8258&rft.eissn=1095-6859&rft_id=info:doi/10.1016/j.ygyno.2009.12.029&rft_dat=%3Cproquest_cross%3E733802672%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c479t-f63c3aecd65aeff37456a8462eddb50eb8c3c513289320c15bdcf0cf7eae633e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=733802672&rft_id=info:pmid/20096921&rfr_iscdi=true |